Product / Device

Cimicifuga racemosa preparation

Overview

Active Ingredient
black cohosh extract
RxNorm CUI
236665

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

72 trials linked to this intervention

72
Total Trials
12
Recruiting
22
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy of Gonadotropin Treatment for Induction of Spermatogenesis in Men With Pathologic Gonadotropin Deficiency: A Meta-Analysis.
Muir Christopher A, Zhang Ting, Jayadev Veena et al. · Clin Endocrinol (Oxf) · 2025
PMID: 39445789Meta-Analysis
The effectiveness of yoga on menopausal symptoms: A systematic review and meta-analysis of randomized controlled trials.
Wang Hongjuan, Liu Yaqian, Kwok Jojo Yan Yan et al. · Int J Nurs Stud · 2025
PMID: 39467491Meta-Analysis
Gonadotropin Therapy for Mini-Puberty Induction in Male Infants With Hypogonadotropic Hypogonadism.
Rhys-Evans Sophie, d'Aniello Francesco, Alexander Emma C et al. · J Clin Endocrinol Metab · 2025
PMID: 39673783Meta-AnalysisFull text (PMC)
Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis.
Menegaz de Almeida Artur, Oliveira Paloma, Lopes Lucca et al. · Obstet Gynecol · 2025
PMID: 39746208Meta-Analysis
Fezolinetant's efficacy and safety in treatment of vasomotor symptoms in postmenopausal women: a meta-analysis and GRADE evaluation of randomized controlled trials.
Allam Abdallah R, Alhateem Mohamed Salah, Mahmoud Abdelrahman Mohamed · Eur J Med Res · 2025
PMID: 39849636Meta-AnalysisFull text (PMC)
Efficacy and safety of elinzanetant in vasomotor symptoms associated with menopause: A meta-analysis of randomized controlled trials.
Sobral Milene Vitória Sampaio, Rocha Paula, Rodrigues Livia Kneipp et al. · Eur J Obstet Gynecol Reprod Biol · 2025
PMID: 39919442Meta-Analysis
Efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis.
de Oliveira Helen Michaela, Diaz Camilo André Viana, Barbosa Lucas Mendes et al. · Maturitas · 2025
PMID: 39987726Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Product / Device
Fully Specified Name
Cimicifuga racemosa preparation (product)
SNOMED CT
412589009
UMLS CUI
C0771967
RxNorm CUI
236665

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

4
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
72
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.